Results for tag: "Myelodysplastic Syndrome Drugs"

Myelodysplastic Syndrome (MDS) is a type of cancer that affects the bone marrow and blood cells. It is a rare disorder that can lead to anemia, infections, and bleeding. Treatment for MDS includes chemotherapy, radiation therapy, and stem cell transplantation. Drugs used to treat MDS include hypomethylating agents, such as azacitidine and decitabine, and immunomodulatory agents, such as lenalidomide and pomalidomide. These drugs are used to reduce the risk of disease progression and improve the quality of life for patients. The Myelodysplastic Syndrome Drugs market is a part of the larger Oncology Drugs market. It is a rapidly growing market, driven by the increasing prevalence of MDS and the development of new drugs. The market is expected to continue to grow in the coming years, as new drugs are developed and approved for use. Some of the major companies in the Myelodysplastic Syndrome Drugs market include Celgene Corporation, Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc., and Merck & Co. Inc. Show Less Read more